Filing Flows › Maxcyte (MXCT) › Guidance history
Maxcyte (MXCT) guidance history: what it guided and what it reported
Maxcyte gave guidance in 3 earnings releases on file since May 12, 2026. Its releases raised guidance once and lowered it 0 times.
Revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $30.0M–$32.0M (May 12, 2026) → reaffirmed $30.0M–$32.0M (Aug 12, 2026) | — | to be reported | — |
Adjusted revenue
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $30.0M–$32.0M (May 12, 2026) → lowered $25.0M–$27.0M (Aug 12, 2026) → raised $34.0M (Oct 14, 2026) | — | to be reported | — |
The latest quarter
Maxcyte, Q2 2026: revenue $7.3M (-14% year over year), operating margin -140.7%, net loss $8.9M, operating cash flow −$4.7M. The chart follows the revenue to costs, profit and cash.
Questions
Does Maxcyte beat its guidance?
Maxcyte gave guidance in 3 earnings releases on file since May 12, 2026. Its releases raised guidance once and lowered it 0 times.
How often does Maxcyte raise guidance?
Its earnings releases raised guidance once and lowered it 0 times since May 12, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.